Introduction {#s1}
============

Mental disorders are the leading cause of years lived with disability ([@CIT0064]). Depressive disorders accounted for 40.5% of disability-adjusted life years caused by mental disorders, with anxiety disorders accounting for another 14.6% and alcohol use disorders for 9.6%. Alcohol use is the leading risk factor for global disease burden in Eastern Europe, Andean Latin America, and southern sub-Saharan Africa ([@CIT0038]), and comorbidity of alcohol use disorders with anxiety and affective disorders has been extensively documented (for review, see [@CIT0006]).

The risk for a lifetime history of anxiety, affective, and alcohol use disorders is strongly influenced by genetic factors. Genetic epidemiological studies report heritability estimates about 30--50% in the case of anxiety disorders ([@CIT0055]) and about 30 to 40% for depression ([@CIT0010]). Twin and family studies largely provide evidence for the shared etiology of affective and anxiety disorder symptoms ([@CIT0062]). For a lifetime history of alcohol abuse and dependence, the estimates of heritability range around 30% in adolescents and 45 to 65% in adults (reviewed by [@CIT0061]).

Monoamine systems undergo extensive and interdependent functional reorganization as affective disorders develop (eg, [@CIT0024]). Several functional polymorphisms in the monoaminergic (dopaminergic, serotonergic, and noradrenergic) systems have been reported to moderate anxiety and affective disorders (for review, see [@CIT0035]) and alcohol use ([@CIT0022]). Although deviations in monoaminergic function probably vary between disorders, a common source of vulnerability could lie in the vesicular function that controls monoamine storage and homeostasis. Vesicular monoamine transporters (VMATs) carry monoamines such as serotonin, dopamine, adrenaline, noradrenaline, and histamine from the cytoplasm into storage vesicles ([@CIT0020]). Hence, VMATs are an important target for biological research in psychiatric disorders ([@CIT0039]; [@CIT0065]).

Two structurally related but pharmacologically distinct human VMATs have been identified, encoded by separate genes, *VMAT1* (*SLC18A1*) located on chromosome 8p21 and *VMAT2* (*SLC18A2*) on chromosome 10q25 ([@CIT0051]). It was initially reported that only VMAT2 is expressed in the brain ([@CIT0052]; [@CIT0021]). However, it was later found that VMAT1 is also widely expressed in human brain at the mRNA and protein level ([@CIT0040]). The transporters share common substrates with the exception of histamine, which is believed to be preferentially packaged by VMAT2 (for review, see [@CIT0002]). They also differ in affinities: VMAT1 shows higher affinity for serotonin ([@CIT0007]).

As reviewed by [@CIT0040], studies in vitro show that lithium and valproate, effective pharmacotherapies for bipolar disorder, increase the expression of VMAT1, suggesting that the VMAT1 might be a target for therapeutic drug action. Variations in the VMAT1 gene can affect transporter function and/or expression and therefore be involved in the etiology of neuropsychiatric disorders. Indirect evidence that the VMAT is involved in psychiatric disorders stems from positron emission tomography imaging studies. Binding of radiolabelled dihydrotetrabenazine, a catecholamine depleter with higher VMAT2 than VMAT1 affinity ([@CIT0014]), was found to be increased in thalamus and brainstem of bipolar patients when compared with controls ([@CIT0068]). Binding in ventral brainstem was higher in bipolar and schizophrenia patients compared with controls ([@CIT0069]). Several recent genetic case-control studies have documented an association between common missense variations in the VMAT1 gene and susceptibility to bipolar disorder ([@CIT0040]) and schizophrenia ([@CIT0005]; [@CIT0008]; [@CIT0041]).

A common single nucleotide polymorphism in the VMAT1 gene (rs1390938 G/A) that results in threonine or isoleucine at amino acid 136 (Thr136Ile) has recently been shown to be functional in vitro, with the 136Ile variant leading to increased monoamine transport into presynaptic vesicles ([@CIT0032]). Thr136Ile polymorphism is located in the intravesicular loop 1, and the frequency of the hyperfunction allele (A; 136Ile) is \~0.25 in European and Caucasian samples and \<0.1 in African samples. It was reported by [@CIT0043] that carriers of the 136Ile (A) variant show diminished hemodynamic responses to negative emotional words in the medial prefrontal cortex and pregenual anterior cingulate cortex when compared with Thr136 homozygotes, suggesting that the *VMAT1* hyperfunction allele may predispose certain individuals to a diminished cortical response to negative stimuli. An association of the 136Thr variant with bipolar disorder ([@CIT0040]) and higher self-report State-Trait Anxiety Inventory (STAI) scores in Thr/Ile heterozygous females ([@CIT0042]) has been described previously.

Based on these previous associations of the variation in the VMAT1 encoding gene to anxiety-related personality traits and bipolar disorder, we tested the hypothesis that *VMAT1* rs1390938/Thr136Ile polymorphism is associated with anxiety and affective disorders, making use of a population-representative sample of young adults. Considering that increased impulsivity and neuroticism are vulnerability markers for bipolar disorder ([@CIT0029]; [@CIT0063]) and symptoms of anxiety and depressiveness have been associated with problematic alcohol use ([@CIT0016]; [@CIT0019]), we also examined the association between rs1390938 polymorphism and impulsivity, personality traits, and alcohol consumption.

Methods {#s2}
=======

Study Population {#s3}
----------------

The study was carried out on the sample of the longitudinal Estonian Children Personality Behaviour and Health Study (ECPBHS), initially cohorts of 9- (born in 1988/1989, recalled at ages 15 and 18 years) and 15- (born in 1982/1983, recalled at ages 18 and 25 years) year-old children. The rationale and procedure of sample formation have been described elsewhere ([@CIT0024]; [@CIT0059]). ECPBHS is population representative, while 79.1% of subjects of the randomized regional sample participated in the original sampling. Most of the present analysis is focused on data from the older cohort, but relevant measures in both cohorts were subject to analysis if available. The complete number of subjects for whom all data used in this analysis were available is shown in [Table 1](#T1){ref-type="table"}. The participants were all of Caucasian descent.

###### 

*VMAT1* rs1390938 Genotype Frequencies in the Entire Sample

                                 AA         AG          GG
  ------------------------------ ---------- ----------- -----------
  Older birth cohort (n=654)     76 (12%)   279 (43%)   299 (45%)
  Younger birth cohort (n=579)   52 (9%)    265 (46%)   262 (45%)

The study was approved by the Ethics Review Committee on Human Research of the University of Tartu, and written informed consent was obtained from all the participants, and in case of minors, also from their parents.

Lifetime Prevalence of Affective, Anxiety, and Alcohol Use Disorders {#s4}
--------------------------------------------------------------------

Psychiatric assessment based on DSM-IV was carried out in the older cohort at age 25 by experienced clinical psychologists using the Mini-International Neuropsychiatric Interview (M.I.N.I.5.0.0; [@CIT0054]; Estonian version: [@CIT0056]) at age 25 years.

Anxiety {#s5}
-------

In the younger birth cohort, the Spielberger State Anxiety Inventory (STAI-S; [@CIT0058]) was used at ages 15 and 18 years and the Spielberger Trait Anxiety Inventory (STAI-T) at age 18 years. In the older birth cohort, STAI-S was used only at 25 years and STAI-T at ages 18 and 25 years.

Depressiveness {#s6}
--------------

Beck Depression Inventory ([@CIT0001]) was used to measure depressiveness in the younger birth cohort at age 15 years. Montgomery--Åsberg Depression Rating Scale MÅDRS ([@CIT0046]) was used in the younger cohort at age 18 yeras and in the older birth cohort at ages 18 and 25 years.

Impulsivity {#s7}
-----------

Self-reports for different facets of impulsivity were completed at ages 15 and 18 yeras for the younger cohort and at ages 18 and 25 years for the older cohort. The Adaptive and Maladaptive Impulsivity Scale, which follows the concept of functional and dysfunctional impulsivity ([@CIT0018]) and comprises subscales measuring fast decision-making and excitement seeking (functional or adaptive impulsivity) and disinhibition and thoughtlessness (dysfunctional or maladaptive impulsivity), was used ([@CIT0033]).

Personality {#s8}
-----------

Personality traits of the 5-factor model ([@CIT0009]) were measured by self-reports with the Estonian version of Revised NEO Personality Inventory (NEO-PI-R) ([@CIT0030]) called EPIP-NEO ([@CIT0047]), or Estonian Brief Big Five Inventory (EBBFI) ([@CIT0036]; [@CIT0025]). EPIP-NEO is a semantically simplified full-length version of NEO-PI-R, whereas EBBFI is a shorter and semantically simplified questionnaire. Personality data of the younger cohort were collected at ages 15 (EPIP-NEO) and 18 years (NEO-PI-R) and of the older cohort at age 15 years (EBBFI) and 18 and 25 years (both NEO-PI-R). As the data have been collected with different instruments, all scores were transformed into Z-scores for statistical analysis.

Alcohol Use {#s9}
-----------

Subjects reported the age when they first consumed one-half a unit of alcohol during both follow-up studies. One unit of alcohol was defined as a glass of light wine or champagne (12 cL), a shot of vodka (4 cL), or a bottle (33 cL) of light alcohol (beer, long drink, cider, etc.). In all data collection waves, the participants reported how often they had consumed different types of alcoholic beverages. According to the most frequently consumed type of alcoholic beverage, a 5-point total alcohol use scale was constructed: (1) almost never, (2) less than monthly, (3) monthly, (4) weekly, (5) every day, as previously described in [@CIT0044].

Genotyping {#s10}
----------

Genomic DNA was extracted from whole blood samples using Qiagen QIAamp DNA Blood Midi Kit. Genotyping was performed on the Applied Biosystems ViiA 7 Real-Time PCR System using TaqMan Pre-Designed SNP Genotyping Assay and Solis BioDyne 5x HOT FIREPol Probe qPCR Mix Plus (ROX). All DNA samples were successfully genotyped. Genotype frequencies were in Hardy-Weinberg equilibrium ([Table 1](#T1){ref-type="table"}).

Statistical Analysis {#s11}
--------------------

Categorical measures were compared by Pearson's chi-square tests. Categorical variable relations to continuous variable were explored with ANOVA and presented as F-statistic, raw *P* value and eta-squared (*η* ^*2*^) as a measure of effect size. Fisher's least significance difference method was used in posthoc comparisons. Contrasts were calculated for significant model effects. All *P* values are reported as 2-tailed, and results are considered significant at the *P*\<.05 level. Statistical analyses were performed using IBM SPSS Statistics, Version 20.

Results {#s12}
=======

The lifetime prevalence of affective, anxiety, and alcohol use disorders was similar to comparable epidemiological studies ([@CIT0027]; [@CIT0017]; WHO, 2014; NIMH, 2015; for a more detailed information of the prevalence of affective and anxiety disorders in the ECPBHS, see [@CIT0034]). *VMAT1* was associated with the prevalence of psychiatric disorders: the likelihood of having been diagnosed with an affective, anxiety, and/or alcohol use disorder at some point of their life was significantly lower for the AA homozygotes compared with G allele carriers ([Table 2](#T2){ref-type="table"}).

###### 

*VMAT1* rs1390938 Effects on Lifetime Prevalence of Affective, Anxiety, and Alcohol Use Disorders

  **Psychiatric Disorder**                **Total**   **Main Statistics (Pearson's χ** ^**2**^)       **AA**         **AG**         **GG**
  --------------------------------------- ----------- ----------------------------------------------- -------------- -------------- -------------
  Affective disorders                     114 (23%)   χ^2^=(2, n=501)=4.86, *P* = .088                10 (16%)       41 (20%)       63 (27%)
  Anxiety disorders                       84 (17%)    χ^2^=(2, n=501)=3.85, *P* = .146                5 (8%)         37 (18%)       42 (18%)
  Affective or anxiety disorder or both   152 (30%)   χ^2^=(2, n=501)=4.52, *P* = .104                12 (19%)       63 (30 %)      77 (33%)
  AUD                                     95 (19%)    χ^2^=(2, n=501)=2.15, *P* = .341                8 (13%)        44 (21%)       43 (19%)
  Affective, anxiety, and/or AUD          214 (43%)   *χ* ^*2*^=(*2*, n=*501*)=*6.78*, *P* = .*034*   *17* (*27%*)   *94* (*45%*)   *103 (45%*)

Abbreviations: AUD, alcohol use disorder.

Significant difference in prevalence presented in italics.

STAI-S scores at age 25 years in the older birth cohort were associated with the *VMAT1* rs1390938 genotype ([Figure 1](#F1){ref-type="fig"}). AA homozygotes received lower STAI-S scores compared with G allele carrier groups \[F(2,472)=3.2, *P*=.041, *η* ^*2*^=0.013\]. Association of the *VMAT1* rs1390938 with STAI-T scores at the age of 25 years in the older birth cohort appeared similar, but the genotype main effect did not reach the level of statistical significance \[F(2,474)=2.6, *P*=.078, *η* ^*2*^=0.011\]. At age 18 years, no significant *VMAT1* rs1390938 genotype effects on anxiety scores were identified in either birth cohort.

![The association of *VMAT1* rs1390938 polymorphism and anxiety scores in the older birth cohort at ages 18 and 25 years. Whiskers denote standard errors of mean. Significant differences between groups: \**P* \< .05.](ijnppy_pyw013_f0001){#F1}

Findings were similar in the case of depressiveness ([Figure 2](#F2){ref-type="fig"}): AA homozygotes reported significantly lower MÅDRS scores than the G allele carrier groups in the older birth cohort at the age of 25 years \[F(2,535)=4.6, *P*=.011, *η* ^*2*^=0.017\].

![The association of *VMAT1* rs1390938 polymorphism and depressiveness in the older birth cohort at the ages 18 and 25 years. Whiskers denote standard errors of mean. Significant differences between groups: \*\**P* \< .01.](ijnppy_pyw013_f0002){#F2}

In the older birth cohort by the age of 25 years, the *VMAT1* rs1390938 genotype was also found associated with maladaptive impulsivity ([Figure 3](#F3){ref-type="fig"}), the AA homozygotes reporting lower thoughtlessness \[F(2,507)=4.0, *P*=.02, *η* ^*2*^=0.015\], and overall maladaptive impulsivity scores \[F(2,507)=3.9, *P*=.022, *η* ^*2*^=0.015\] than G allele carriers. Adaptive impulsivity was not influenced by *VMAT1*.

![The association of *VMAT1* rs1390938 polymorphism and thoughtlessness scores in the older birth cohort at the ages 18 and 25 years. Whiskers denote standard errors of mean. Significant differences between groups denoted as follows: \**P* \< .05, ^\#^ *P* = .062.](ijnppy_pyw013_f0003){#F3}

Of the 5-factor model personality traits, *VMAT1* was associated only with neuroticism ([Figure 4](#F4){ref-type="fig"}). In the older birth cohort at age 25 years, AA homozygotes reported lower neuroticism scores than G allele carriers \[F(2,492)=3.7, *P*=.025, *η* ^*2*^=0.015\]. At age 18 years, no significant *VMAT1* rs1390938 genotype effects on personality scores were identified in either birth cohort.

![The association of *VMAT1* rs1390938 polymorphism and neuroticism scores in the older birth cohort at the ages 18 and 25 years. Whiskers denote standard errors of mean. Significant differences between groups denoted as follows: \**P* \< .05, \*\**P* \< .01.](ijnppy_pyw013_f0004){#F4}

*VMAT1* rs1390938 genotype did not affect the self-reported measures of the frequency of alcohol use in different ages (data not shown). However, *VMAT1* was associated with the average age when the subjects reportedly first consumed one-half a unit of alcohol in both younger \[F(2,488)=3.0, *P*=.053, *η* ^*2*^=0.012\] and older \[F(2,578)=4.2, *P*=.015, *η* ^*2*^=0.014\] birth cohorts, but in opposite directions ([Figure 5](#F5){ref-type="fig"}). In the younger birth cohort, GG homozygotes were the first and AA homozygotes the last to start experimenting; in the older cohort, it was the other way around. The younger birth cohort generally started experimenting with alcohol at an earlier age than the older birth cohort \[F(1,1070)=96.0, *P*\<.001, *η* ^*2*^ *=*0.082\] with the exception of the*VMAT1* rs1390938 AA homozygotes. Consistently, at age 15 years, the younger cohort was using alcohol more frequently than the older cohort. Alcohol use frequency was not, however, statistically significantly different at age 18 years (data not shown). Subjects in the older cohort diagnosed with alcohol use disorder by age 25 years reported experimenting with alcohol at an earlier age (13.4±0.3) than the rest of the sample \[14.4±0.1; F(1,488)=13.7, *P*\<.001, *η* ^*2*^=0.027\].

![The association of *VMAT1* rs1390938 polymorphism in interaction with birth cohort with the average age when the subjects reportedly first consumed one-half a unit of alcohol \[F ~*VMAT1*\ rs1390938\ \*\ cohort~ (2,1066)=6.9, *P* = .001, *η* ^*2*^ *=*0.013\]. The dashed line indicates the mean age when the subjects from the respective cohort first consumed one-half a unit of alcohol. Whiskers denote standard errors of mean. Significant differences between groups denoted as follows: \**P* \< .05, \*\*\**P* \< .001.](ijnppy_pyw013_f0005){#F5}

Discussion {#s13}
==========

In this study, we tested the hypothesis that the *VMAT1* rs1390938/Thr136Ile polymorphism is associated with mood disorders, alcohol use, and personality. We found that subjects with the AA (Ile/Ile) genotype were less likely to have been diagnosed with an affective, anxiety, and/or alcohol use disorder at some point of their life and reported lower state and trait anxiety, depressiveness, maladaptive impulsivity, and neuroticism by young adulthood compared with G allele carriers. In addition, while initiation of alcohol use is taking place at progressively younger ages ([@CIT0011]; [@CIT0050]; [@CIT0060]; present findings), this did not occur in AA homozygotes. All these associations were similar for men and women. Our results are essentially consistent with previous research. It has been found that the gain-of-function A-allele (136Ile) is protective against bipolar disorder ([@CIT0040]), and the AA (Ile/Ile) homozygotes have lower STAI state and trait scores ([@CIT0042]). Very recently, the A-allele (136Ile) has been found to be associated with reduced connectivity in networks that show a general increased connectivity in alcoholics, indicating a potential protective effect ([@CIT0067]).

Genetic variation in plasma membrane transporters (serotonin, noradrenaline, and dopamine transporters) can serve as a basis for inter-individual differences in brain circuits associated with affective behavior ([@CIT0003]). These transporters are mainly involved in synaptic neurotransmitter reuptake, which contributes to the duration of signaling. In contrast, variation in the magnitude of signaling may be more closely related to mechanisms regulating synaptic neurotransmitter release ([@CIT0043]). Efficient reuptake of the transmitter from the synaptic cleft through plasma membrane monoamine transporters followed by reaccumulation into synaptic vesicles through the VMATs constitute crucial interlinked steps of monoamine neurotransmission ([@CIT0065]).

The common Thr136Ile polymorphism is located in the first luminal domain of the transporter. This region of the protein interacts with inhibitors and substrates ([@CIT0057]) and mediates G-protein-dependent regulation of transmitter uptake ([@CIT0007]). 136Thr has been related to decreased monoamine transport in vitro ([@CIT0032]; [@CIT0043]). Reduced storage and release of monoamines in brain regions expressing VMAT1 and in adrenal medulla where VMAT1 is the major type of VMAT have been suggested to alter the balance of monoamine availability both peripherally and centrally ([@CIT0032]). Such presynaptic components are likely part of a shared pathway of vulnerability to a range of neuropsychiatric phenotypes ([@CIT0043]).

While the association of *VMAT1* rs1390938/Thr136Ile polymorphism with psychological measures and prevalence of psychiatric disorders in this sample is straighforward and the findings provide a remarkably coherent picture, an interesting observation was the interaction with birth cohort in the mean age when subjects reportedly first consumed one-half a unit of alcohol. Younger age at first use of alcohol has been associated with significantly higher risk of heavy alcohol use ([@CIT0037]). In the younger birth cohort of the ECPBHS, GG homozygotes were the first and AA homozygotes the last to start experimenting; in the older cohort, this was completely reversed. Unlike in the case of G allele carriers, there was no cohort difference in the mean age when AA homozygotes started experimenting with alcohol. Given that peer drinking serves as a model for alcohol use ([@CIT0045]) and socially anxious youth can be motivated to use alcohol to manage their anxious arousal ([@CIT0004]), one possible explanation could be that AA homozygotes may be less sensitive to peer pressure in this regard. As described before, it was determined by [@CIT0043] that carriers of the *VMAT1* hyperfunction allele (A) may be predisposed to a diminished cortical response to negative stimuli. Activity of prefrontal regions is a critical component of regulating emotional arousal, particularly those triggered in response to environmental factors.

Belonging to a particular birth cohort can serve as a proxy for the socioeconomic environment experienced by a generation. Alcohol consumption has been shown to be subject to birth cohort effects ([@CIT0028]; [@CIT0053]; [@CIT0049]). Economic fluctuation, political instability, policies and laws, and social norms are group-level exposures that can vary between time periods and countries, potentially impacting particular birth cohorts in ways that affect their risk for higher alcohol consumption and alcohol use disorder ([@CIT0031]). In a previous analysis, we found that expression of genetic vulnerability to alcohol use is influenced by birth cohort effects. We demonstrated that the serotonin transporter gene promoter polymorphism (5-HTTLPR) is associated with alcohol consumption in the general population, but the effect is dependent on birth cohort and gender ([@CIT0060]). In this instance, the female s/s homozygotes were the most changeable group across the 2 birth cohorts, and this group could be interpreted as the most susceptible to peer pressure. The country of the present study, Estonia, is a representative transition society that moved away from socialism in the late 1980s and became an independent and highly liberal economy since 1991. The Estonian economy was one of the fastest growing in the world until 2007 ([@CIT0066]), bringing about rapid but multifaceted social changes. Therefore, environmental conditions and demands have been rather different for the 2 birth cohorts, bringing about a change in the E component of the G × E formula; in turn, such a change in environment indeed should be reflected in how specific gene variants relate to the behavior in question, in this case, alcohol use initiation ([@CIT0023]). Thus, one could speculate that in the condition of increased alcohol availability, the shift toward a younger age of alcohol use mediated by peer pressure is better resisted by the AA homozygotes.

These results should be interpreted in the context of limitations. First, we used self-reports for the majority of measurements. However, the results with the self-reports fall in line with our previous data based on parents' and teachers' ratings of personality and are consistent with findings based on clinical interview. Another limitation of the study is the small group sizes in the case of AA homozygous subjects diagnosed with affective, anxiety, or alcohol use disorders. This may lead to insufficient power and type II error when genotype effects on separate diagnosis are analyzed. Nevertheless, the strength of the present study is the longitudinal design, rigorous questionnaire data collection performed in uniform conditions of the laboratory, and the fact that the sample has a strong representation of regional population.

In conclusion, we have found that the *VMAT1* rs1390938/Thr136Ile polymorphism is associated with mood, personality, and alcohol use in the general population. Subjects homozygous for the hyperfunction allele (AA; Ile/Ile) appear to have features supporting resiliency to negative emotionality and these disorders.
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